PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details​​​​​​.
CLICK HERE regarding the Change Healthcare update.

Clinical Research & Trials

USO 18283

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

 

Disease Types: Genitourinary Cancer Research

Eligibility Requirements:

-locally advanced or metastatic urothelial cancer with measurable disease
-No: immunodeficiency disease; prior anti-cancer with mono-clonal antibodies within last 4 weeks; prior treatment with irinotecan; known active CNS metastasis or carcinomatous meningitis; active serious cardiac disease (MI or unstable angina within last 6 months, serious ventricular arrhythmia, congestive heart failure class 3 or 4, ejection failure less than 40%); chronic ulcerative colitis, Crohn’s disease, or history of bowel obstruction; prior history of significant bleeding, intestinal obstruction, or GI perforation within last 6 months; known HIV, Hep B or Hep C

Available at: